patient

I am a hematologist specializing in the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN) and clonal cytopenias of unknown significance. I received my Master of Science in pathobiology and molecular medicine from the University of Cincinnati, and completed a fellowship in hematology/oncology at the University of Alabama. As a member of the Leukemia Research Program at the OSUCCC – James, my clinical and translational research focus is on novel therapeutics in myeloid diseases, with a special focus in disease progression from

My research focuses on identifying the genetic causes of human diseases as a means to both better diagnosis and treat patients and understand basic biologic principles. We are interested in studying autoimmune and auto-inflammatory diseases to elucidate the mechanism underlying these diseases and improve patient care. We use a combination of genetic, and biochemical approaches in patient derived and animal models to better understand these diseases. Our aim is to directly connect human diseases with basic innate immune biology using genetics.

Dr. Balasubramanian completed his medical training at Madras Medical College in India. His interest in treating malignant hematology patients started in his advanced training in Singapore in the Department of Hematology and Bone Marrow Transplant. He was intrigued by the advancement of cancer genetics and its application in the development of novel therapeutics. He strongly believes in the concept of being a physician-scientist. He completed a year of clinical research fellowship in Neuro-Oncology at Cleveland Clinic, where he investigated the role of EGFR mutations and ALK rearrangement in

Dr. Catherine Lee's clinical expertise is in Blood and Marrow Transplantation (BMT) & Cellular Therapy. She specializes in autologous and allogeneic hematopoietic cell transplants for the treatment of malignant and benign hematologic diseases in adult patients. She also directs the clinical cellular therapy program and provides both standard-of-care cellular therapy treatments and those being tested in clinical trials. Furthermore, she leads the Chronic Graft-versus-Host Disease/Long-Term Follow-Up Program for patients who have received hematopoietic cell transplantation or other immune